ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO363

Soluble Urokinase Plasminogen Activation Receptor (suPAR) in the German Chronic Kidney Disease (GCKD) Study

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 301 CKD: Risk Factors for Incidence and Progression


  • Sommerer, Claudia, University Hospital of Heidelberg, HEIDELBERG, Germany
  • Metzendorf, Nicole Gisela, Kidney Center Heidelberg, Heidelberg, Germany
  • Schmid, Matthias, University of Bonn, Bonn, Germany
  • Eckardt, Kai-Uwe, University of Erlangen-Nuremberg, Erlangen, Germany
  • Reiser, Jochen, Rush University Medical Center, Chicago, Illinois, United States
  • Zeier, Martin G., University Hospital of Heidelberg, HEIDELBERG, Germany

Group or Team Name

  • On behalf of GCKD investigators

Soluble urokinase plasminogen activation receptor (suPAR) is an emerging biomarker for prediction and progression of kidney disease and cardiovascular events. The value of suPAR as a biomarker was evaluated in the large prospective observational German Chronic Kidney Disease (GCKD) study.


Chronic kidney disease (CKD) patients aged 18-76 years with an estimated glomerular filtration rate (eGFR) of 30 - <60 mL/min/1.73 m2 or eGFR≥60 and overt proteinuria were enrolled in the GCKD study. suPAR was measured in baseline samples of participants and categorized in quintiles for investigation of the underlying disease, age and renal function.


A total of 4994 CKD patients were studied (60.09 % males, mean age 60.08 ±11.98 years). Mean eGFR was 49.47 ± 18.29 mL/min/1.73 m2 and median (IQR) albumin/creatinine ratio was 50.85 (25% quantile: 9.61, 75% quantile 387.17) mg/g. Mean suPAR level was 2184±1952 pg/mL with a range from 221 to 45433 (median 1771, 25% quantile: 1446.9, 75% quantile: 2254.1). Prevalence of patients with cardiovascular diseases, diabetic nephropathy, systemic diseases and smoking showed an upwards trend from suPAR quintile 1 to quintile 5. Median suPAR concentration increased with worsening renal function (CKD stage 1 to CKD stage 4, p<0.0001) and age (p<0.0001). Within CKD categories, suPAR rised with increase of albuminuria.


suPAR was evaluated in one of the worldwide largest CKD cohorts. In this study cohort, suPAR was associated with underlying cardiovascular disease, diabetic nephropathy as well as systemic disease involving the kidney. suPAR depended on renal function, proteinuria and age. The predictive value of suPAR on development of renal function and cardiovascular disease will be evaluated in this prospective study.